n6022
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01147406)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CHRNA7 inhibitor
- Alcohol dehydrogenase class IIIINHIBITOR
Alcohol dehydrogenase class III inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1- Mol. weight
- 414.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1738699 ↗
Also known as
- n6022
- n6022
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01746784 | Phase 1 | Feb 1, 2014 | Nivalis Therapeutics, Inc., University of North Carolina at Chapel Hill |
| NCT01339897 | Phase 1 | Apr 1, 2011 | Nivalis Therapeutics, Inc., Parexel |
| NCT01147406 | Phase 1 | Aug 1, 2010 | Nivalis Therapeutics, Inc., Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nivalis Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2010 |
| Parexel | For profit | 2 | 0 | 1 | 2010 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1